Modality
Gene Therapy
MOA
Anti-Aβ
Target
LAG-3
Pathway
Incretin
Atopic Derm
Development Pipeline
Preclinical
~Feb 2011
→ ~May 2012
Phase 1
~Aug 2012
→ ~Nov 2013
Phase 2
~Feb 2014
→ ~May 2015
Phase 3
~Aug 2015
→ ~Nov 2016
NDA/BLA
~Feb 2017
→ ~May 2018
Approved
Aug 2018
→ Dec 2029
ApprovedCurrent
NCT05614649
255 pts·Atopic Derm
2020-08→2028-05·Active
NCT04148082
2,747 pts·Atopic Derm
2019-02→TBD·Active
NCT08485701
1,235 pts·Atopic Derm
2018-08→2029-12·Recruiting
4,237 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2028-05-152.1y awayPh3 Readout· Atopic Derm
2029-12-093.7y awayPh3 Readout· Atopic Derm
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Recruit…
Approved
Active
Approved
Active
Catalysts
Ph3 Readout
2028-05-15 · 2.1y away
Atopic Derm
Ph3 Readout
2029-12-09 · 3.7y away
Atopic Derm
RecruitingActive|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05614649 | Approved | Atopic Derm | Active | 255 | NT-proBNP |
| NCT04148082 | Approved | Atopic Derm | Active | 2747 | PANSS |
| NCT08485701 | Approved | Atopic Derm | Recruiting | 1235 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| RLA-6817 | Relay Therapeutics | Phase 3 | TIGIT | |
| Lisoosocimab | Zealand Pharma | Approved | KIF18A |